ResultsIQ

ResultsIQ › Latest results › Suraksha Diagnostic Limited

Suraksha Diagnostic Limited Q2 FY26 results deck summary

NSE: SURAKSHA · BSE: 544293

Results deck of 10 Nov 2025, summarised by AI from the filing.

Suraksha Diagnostic Q2 FY26 revenue rose 17% YoY to ₹796 million; margins expected to normalize as new centres mature.

Key takeaways

  1. Q2 FY26 revenue Total income rose 17% YoY to ₹796 million in Q2 FY26.
  2. Margin outlook Management expects margins to return to normal levels as new centres mature and economies of scale set in.
  3. Centre additions Added 5 new centres in Q2 FY26, taking total centre count to 63.
  4. Genomics launch Launched Suraksha Genomics in July 2025 for advanced genetic and molecular testing services.
  5. Margin pressure 21 new centres, including 15 less than a year old, impact the overall EBITDA margin.

Original filing on BSE

Suraksha Diagnostic Limited Q1 FY27 results

As filed: Revenue ₹87.7 cr (+20% year on year), EBITDA ₹30.4 cr (+32% year on year), PAT ₹12.9 cr (+43% year on year), EBITDA margin 34.7% (+322 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹81.4 cr (+25% year on year), EBITDA ₹24.4 cr (+28% year on year), PAT ₹6.2 cr (−12% year on year), EBITDA margin 29.9% (+70 bps). Score 56 of 100, In line with trend. EBITDA margin rose 70 bps year on year. Tax rate 38%. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: −16.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹77.7 cr (+29% year on year), EBITDA ₹23.2 cr (+29% year on year), PAT ₹7.2 cr (+21% year on year), EBITDA margin 29.8% (−19 bps). Score 70 of 100, Above trend. EBITDA margin fell 19 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −9.7% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹79.0 cr (+18% year on year), EBITDA ₹24.0 cr (0% year on year), PAT ₹9.0 cr (−10% year on year), EBITDA margin 30.4% (−544 bps). Score 36 of 100, Below trend. EBITDA margin fell 544 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −13.0% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹70.0 cr, EBITDA ₹24.0 cr, PAT ₹10.0 cr, EBITDA margin 34.3%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹64.0 cr, EBITDA ₹20.0 cr, PAT ₹8.0 cr, EBITDA margin 31.3%. Not scored. No result for the same quarter last year. Share price after the results: −1.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹59.0 cr, EBITDA ₹18.0 cr, PAT ₹6.0 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹66.0 cr, EBITDA ₹24.0 cr, PAT ₹11.0 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Suraksha Diagnostic Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.